In its announcement, which came Friday afternoon, the FDA noted that safety and efficacy of Wegovy in the new indication were based on a trial comprising 17,600 patients randomized to receive either Novos drug or placebo, as well as standard medical treatment and lifestyle counseling
08.01.25 August monthly MDL report: More than 2,000 active cases The number of active claims in the MDL grew past 2,000, marking 2,190 active GLP-1 lawsuits, including Wegovy claims
as the body shrinks, some reduction in muscle is a normal, appropriate adjustment rather than a harmful wasting
On strength testing, he showed antigravity strength in the proximal LLE, severe continued paresis of the distal LLE, and 4/5 on the right lower extremity, although he still complained of decreased sensation bilaterally in his legs
This is not a one size fits all scenario and reflecting No decision about me without me (Department of Health, 2012), the same considerations need to be applied in the PwDs decision to potentially not engage with this group GLP-1 RA start and opt for an individual one- to-one GLP-1 RA start instead.
